查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1967609

組織與器官移植市場－全球產業規模、佔有率、趨勢、機會與預測：按產品、應用、地區和競爭格局分類，2021-2031年

Tissue And Organ Transplantation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球組織和器官移植市場預計將從 2025 年的 186.2 億美元成長到 2031 年的 310.7 億美元，複合年成長率為 8.91%。

此領域涵蓋將供體生物組織或器官移植給受體，以恢復器官衰竭後生理功能的醫療干預措施。市場成長的主要驅動力是全球慢性病（包括心血管疾病和腎臟疾病）發生率的上升，這導致對替代療法的需求顯著增加。此外，醫療基礎設施的加強和更有效的免疫抑制療法的研發也促進了市場成長，這些因素共同提高了術後存活率和患者的長期健康狀況。

市場概覽
預測期 2027-2031
市場規模：2025年 186.2億美元
市場規模：2031年 310.7億美元
複合年成長率：2026-2031年 8.91%
成長最快的細分市場 紙巾製品
最大的市場 北美洲

儘管取得了這些進展，器官移植產業仍面臨一個重大障礙：捐贈者器官嚴重短缺，而等待移植的人數卻在不斷增加。這種供需失衡造成了嚴重的瓶頸，嚴重限制了每年可進行的移植手術數量，儘管臨床需求量很大。根據全球捐贈與移植觀察站的數據，2024年全球整體進行了172,397例固態器官移植手術。這一數字凸顯出，器官供應不足仍然是滿足日益成長的國際移植手術需求的一大挑戰。

市場促進因素

外科手術技術和器官保存技術的創新是推動市場擴張的核心動力。尤其值得注意的是，捐贈器官在體外存活時間的延長。諸如常溫機械灌注等先進技術能夠使器官在運輸過程中保持功能，最大限度地減少缺血性損傷，並使以前被認為無法使用的器官得以利用。從靜態冷凍保存轉向動態保存系統提高了器官利用率，並簡化了複雜的物流操作。例如，Transmedics集團在其2024年10月發布的2024年第三季財報中報告稱，由於其專有的肺、心臟和肝臟器官護理系統在臨床上的應用範圍擴大，收入淨額顯著成長至1.088億美元。

慢性疾病，尤其是末期腎功能衰竭和肝功能衰竭衰竭的日益普遍，進一步加劇了對生物替代療法的迫切需求。人口老化、生活方式改變以及高血壓和糖尿病的增加等因素，加速了患者發展至末期器官衰竭的速度，使他們需要即時進行器官移植。供體器官供應與需要治療的患者數量之間持續存在的缺口，給醫療系統帶來了巨大的壓力，迫使其改進器官獲取工作。根據美國衛生資源與服務管理局 (HRSA) 2024 年 3 月發布的器官捐贈統計數據，超過 10.3 萬名候選人登記在國家移植等待名單上，凸顯了慢性器官衰竭患者的等待現狀。此外，美國器官分配網路 (UNOS) 在 2024 年報告稱，美國上年度完成了超過 4.6 萬例器官移植手術，達到了一個里程碑，這表明美國致力於滿足日益成長的臨床需求。

市場挑戰

供體器官嚴重短缺是限制組織和器官移植市場成長潛力的根本阻礙因素。這種短缺嚴格限制了手術數量，直接限制了醫療設備製造商和移植中心的商機。即使擁有先進的手術基礎設施和高臨床需求，由於無法獲得足夠的手術所需生物材料，市場也難以有效擴張。這種供需缺口導致手術數量成長停滯，造成相當一部分合格的患者無法獲得所需的治療。

近期來自主要移植網路的統計數據凸顯了這一瓶頸的嚴重性，揭示了資源可用性與臨床需求之間的巨大差距。根據2024年器官取得和移植網路（OPTN）的數據，美國國家移植等待名單上有超過10.3萬名候選人。這一數字表明，移植手術的需求遠遠超過現有供給，從根本上阻礙了市場擴張以滿足實際需求。因此，該行業面臨永久性的運作上限，阻礙了這些救命手術本來可以帶來的潛在收入的產生。

市場趨勢

利用基因改造器官進行異種移植的出現，正在創造一種新的可移植組織來源，有望緩解捐贈者嚴重短缺的問題。生技公司正利用基因編輯技術改造豬器官，去除導致排斥反應的抗原，並引入確保生物相容性的人類調控因子。這項進展使器官移植擺脫了對人類捐贈者的依賴，並為那些在等待移植期間面臨高死亡風險的患者提供了一種可擴展的替代方案。根據eGenesis公司於2025年2月發布的最新報告《eGenesis成功完成第二例基因編輯豬腎移植》，該公司已成功完成第二例使用基因編輯腎臟進行的人體移植手術，證明了這種非人類器官的臨床可行性。

同時，微創手術和機器人輔助移植技術正不斷發展，提高了手術精度，並加快了術後恢復。先進機器人平台的引入使外科醫生能夠比開放性手術更靈活地完成複雜的血管吻合術，從而縮短住院時間，並最大限度地減少併發症。這項技術進步不僅改善了臨床療效，也擴大了高風險患者的手術適應症範圍，使那些以往仿單標示外傳統手術的患者也能接受手術。根據直覺外科公司（Intuitive Surgical）於2025年1月發布的“2024年第四季及全年中期業績報告”，2024年全球使用達文西手術系統進行的手術數量成長了約17%，這證實了這些平台正在迅速融入複雜的醫療程序中。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球組織與器官移植市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（組織製品、防腐劑、免疫抑制劑）
    • 透過應用（器官移植、組織移植）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美組織與器官移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲組織與器官移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區組織與器官移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲組織及器官移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲組織與器官移植市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球組織與器官移植市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Artivion, Inc
  • Folio Biosciences LLC
  • Arthrex, Inc.
  • Abbvie Inc.
  • Zimmer Biomet Holdings, Inc.
  • India Medtronic Private Limited
  • Novartis AG
  • Stryker Corporation
  • BiolifeSolutions Inc.
  • Teva Pharmaceutical Industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24301

The Global Tissue And Organ Transplantation Market is projected to expand from USD 18.62 Billion in 2025 to USD 31.07 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 8.91%. This sector covers medical interventions where biological tissues or organs are transferred from a donor to a recipient to restore physiological function following organ failure. The market's upward trajectory is primarily driven by the rising global incidence of chronic ailments, including cardiovascular and renal diseases, which create a substantial need for replacement therapies. Furthermore, growth is reinforced by enhancements in medical infrastructure and the development of more effective immunosuppressive regimens, which collectively improve survival rates and long-term patient health post-surgery.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 18.62 Billion
Market Size 2031USD 31.07 Billion
CAGR 2026-20318.91%
Fastest Growing SegmentTissue Products
Largest MarketNorth America

Despite these advancements, the industry confronts a major obstacle in the form of a severe scarcity of donor organs compared to the expanding waiting lists. This imbalance creates a significant bottleneck that strictly limits the number of procedures that can be conducted each year, even amidst high clinical necessity. Data from the Global Observatory on Donation and Transplantation indicates that in 2024, a total of 172,397 solid organ transplants were performed worldwide. This figure emphasizes the persistent difficulty posed by supply limitations in satisfying the growing international demand for transplant surgeries.

Market Driver

Technological innovations in surgical methods and organ preservation act as a central catalyst for market expansion, notably by prolonging the viability of donor organs outside the human body. Advanced techniques, such as normothermic machine perfusion, enable organs to maintain functionality during transport, which minimizes ischemic damage and allows for the utilization of organs that were previously considered marginal. This transition from static cold storage to dynamic preservation systems increases utilization rates and facilitates complex logistical operations. For instance, TransMedics Group, Inc. reported in their 'Third Quarter 2024 Financial Results' from October 2024 that net revenue reached $108.8 million, a significant increase driven by the rising clinical adoption of their proprietary Organ Care System for lung, heart, and liver programs.

The rising prevalence of chronic conditions, specifically end-stage renal disease and liver failure, continues to heighten the urgent need for biological replacement therapies. Factors such as aging populations, lifestyle choices, and the increasing burden of hypertension and diabetes are quickening the pace at which patients develop terminal organ dysfunction, requiring immediate transplantation. This enduring disparity between the availability of donor grafts and the number of patients needing treatment places immense pressure on healthcare systems to improve procurement efforts. According to the Health Resources and Services Administration's 'Organ Donation Statistics' from March 2024, over 103,000 candidates were on the national transplant waiting list, illustrating the backlog of chronic organ failure patients. Additionally, the United Network for Organ Sharing noted in 2024 that the U.S. reached a milestone by conducting over 46,000 transplants in the prior year, signaling strong efforts to meet this escalating clinical demand.

Market Challenge

The severe insufficiency of available donor organs acts as a fundamental restriction on the growth potential of the tissue and organ transplantation market. This scarcity imposes a hard limit on the number of procedures that can be performed, which directly curtails the revenue opportunities for medical device manufacturers and transplant centers. Even with advanced surgical infrastructure and high clinical demand, the market struggles to scale efficiently because the necessary biological materials for surgeries are not available in adequate numbers. This gap between supply and demand causes a forced stagnation in procedural growth, leaving a substantial segment of the eligible patient population without necessary care.

The scale of this bottleneck is underscored by recent statistics from major transplant networks, which reveal the stark contrast between resource availability and clinical necessity. According to data from the Organ Procurement and Transplantation Network in 2024, there were over 103,000 candidates registered on the national transplant waiting list in the United States. This figure illustrates that the requirement for transplant interventions vastly outstrips the existing supply, mechanically preventing the market from expanding to satisfy the actual population needs. Consequently, the industry encounters a permanent cap on its operational capacity, hindering the generation of potential revenue that would otherwise result from these life-saving operations.

Market Trends

The emergence of xenotransplantation involving genetically engineered organs is creating a novel source of graftable tissues to mitigate the severe donor shortage. Biotechnology firms are deploying gene-editing technologies to alter porcine organs, removing antigens that trigger rejection and incorporating human regulators to guarantee biocompatibility. This progress steers transplantation away from sole reliance on human donors, presenting a scalable alternative for patients who otherwise face high mortality risks while waiting. As reported by eGenesis in February 2025 within their update 'eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney,' the company successfully performed its second human transplant using a gene-edited kidney, validating the clinical feasibility of this non-human source.

Concurrently, the transition toward minimally invasive and robotic-assisted transplant surgeries is refining procedural accuracy and enhancing post-operative recovery. The adoption of sophisticated robotic platforms enables surgeons to execute intricate vascular anastomoses with greater dexterity than open methods, thereby reducing hospital stays and minimizing complications. This technological advancement not only improves clinical results but also extends surgical eligibility to high-risk patients who were previously considered unsuitable for traditional procedures. According to the 'Intuitive Announces Preliminary Fourth Quarter and Full Year 2024 Results' report by Intuitive Surgical in January 2025, global procedures utilizing da Vinci surgical systems increased by roughly 17% in 2024, underscoring the rapid integration of these platforms into complex medical treatments.

Key Market Players

  • Artivion, Inc
  • Folio Biosciences LLC
  • Arthrex, Inc.
  • Abbvie Inc.
  • Zimmer Biomet Holdings, Inc.
  • India Medtronic Private Limited
  • Novartis AG
  • Stryker Corporation
  • BiolifeSolutions Inc.
  • Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Tissue And Organ Transplantation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tissue And Organ Transplantation Market, By Product

  • Tissue Products
  • Preservation Solutions
  • Immunosuppressive Drugs

Tissue And Organ Transplantation Market, By Application

  • Organ Transplantation
  • Tissue Transplantation

Tissue And Organ Transplantation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tissue And Organ Transplantation Market.

Available Customizations:

Global Tissue And Organ Transplantation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tissue And Organ Transplantation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Tissue Products, Preservation Solutions, Immunosuppressive Drugs)
    • 5.2.2. By Application (Organ Transplantation, Tissue Transplantation)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Tissue And Organ Transplantation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Tissue And Organ Transplantation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Tissue And Organ Transplantation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Tissue And Organ Transplantation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Tissue And Organ Transplantation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Tissue And Organ Transplantation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Tissue And Organ Transplantation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Tissue And Organ Transplantation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Tissue And Organ Transplantation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Tissue And Organ Transplantation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Tissue And Organ Transplantation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Tissue And Organ Transplantation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Tissue And Organ Transplantation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Tissue And Organ Transplantation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Tissue And Organ Transplantation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Tissue And Organ Transplantation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Tissue And Organ Transplantation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Tissue And Organ Transplantation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Tissue And Organ Transplantation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Tissue And Organ Transplantation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Tissue And Organ Transplantation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Tissue And Organ Transplantation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Tissue And Organ Transplantation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Tissue And Organ Transplantation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Tissue And Organ Transplantation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Artivion, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Folio Biosciences LLC
  • 15.3. Arthrex, Inc.
  • 15.4. Abbvie Inc.
  • 15.5. Zimmer Biomet Holdings, Inc.
  • 15.6. India Medtronic Private Limited
  • 15.7. Novartis AG
  • 15.8. Stryker Corporation
  • 15.9. BiolifeSolutions Inc.
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer